Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY2023 Earnings Presentation
17 slides from Alembic Pharmaceuticals's earnings presentation, May 5, 2023
Slide 1: Exchange filing cover letter for investors presentation
Date: 5th May, 2023 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 NSE
Slide 2: Alembic Pharmaceuticals Limited Investor presentation – March 2023
Alembic Pharmaceuticals Limited Investor presentation – March 2023 BSE & NSE: APLLTD 1
Slide 3: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 4: Financial Highlights
Financial Highlights INR Bn Before Aleor's accelerated amortization YTD YTD Particulars Q4 FY23 Q4 FY22 Growth Growth Mar'23 Mar'22 YTD Mar'23 YTD Mar'22 Growth Net Sales 14.06 14.16 -1% 56.53 53.06 7% 56.53 53.06 7% EBIDTA Pre R&D 3.16 4.92 -36% 13.01 16.40 -21% 13.01 16.4 -21% Margin % 22% 35% 23%
Slide 5: Revenue snapshot – Q4 & FY23
Revenue snapshot – Q4 & FY23 INR Bn Business Q3FY23 Q4FY23 Q4FY22 Y-o-Y Q-o-Q FY23 FY22 Y-0-Y Key Highlights : Formulations India 5.45 4.90 4.49 9% -10% 20.63 19.26 7% India Branded Business : India Branded Business recorded 9% US 4.32 3.54 5.57 -36% -18% 15.72 16.66 -6% growth with topline of Rs 49
Slide 6: Branded Business
Branded Business Revenue – Q4 FY23 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 20.6 19.3 4.90 4.49 0.61 0.53 15.0 13.8 14.3 Vet 1.70 1.49 Acute Speciality 2.46 2.58 Q4FY22 Q4FY23 FY19 FY20 FY21 FY22 FY23 Marketing organization Key achievements ➢ 5000+ MRs ➢ India Branded Business recorded 9% gro
Slide 7: Branded Business
Branded Business Top Brands with rank and MS% Prescription Business 1294 Leading Brands Other Leading Brands 1093 Rank MAT Rank MAT BRANDS MAT Mar 23 BRANDS MAT Mar Mar 23 Mar 23 MS% 23 MS% YTD Mar 22 AZITHRAL 1 32.1 ELATA 1 41.9 TELLZY 5 4.9 VEHYCAL-XT 4 7.2 YTD Mar 23 WIKORYL 3 10.3 ESTROPLUS 2 39
Slide 8: Therapy-wise Performance Q4 FY23
Therapy-wise Performance Q4 FY23 Q4 FY23 Q4 FY22 Therapy Market Share Alembic Alembic Therapy Alembic Alembic Market Share Therapy Growth % Growth % Growth % Growth Growth % Growth % % (ORG) % (IPM) (ORG) (ORG) (PRIM) % (ORG) (ORG) (PRIM) Gynecology 12 3 24 18 8 2.8 17 21 Cardiology 13 2 10 2 8 1.8
Slide 9: Therapy-wise Performance FY23
Therapy-wise Performance FY23 FY23 FY22 Therapy Market Share Alembic Alembic Therapy Alembic Alembic Market Share Therapy Growth % Growth % Growth % Growth Growth % Growth % % (ORG) % (IPM) (ORG) (ORG) (PRIM) % (ORG) (ORG) (PRIM) Gynecology 14 3.0 29 29 16 2.7 24 23 Cardiology 9 1.8 9 7 11 1.8 5 9 G
Slide 10: Animal Health Business
Animal Health Business Revenue - YTD Mar Revenue - YTD Mar for Major 5 brands CAGR - 26% INR Cr INR Cr 166.7 CAGR 23% ↑ 139.9 111.0 83.3 Animal Health 280 150 FY20 FY23 FY20 FY21 FY22 FY23 Key achievements ➢ Leader in Hematinic Market covering Sharkoferrol Brand ➢ Leader in Anti Biotic Market coveri
Slide 11: US Generic
US Generic INR Bn Revenue – Q4 FY23 INR Bn Revenue – Last 5 Years CAGR - 5% 5.57 21.63 19.76 16.66 3.54 15.72 12.88 Q4FY22 Q4FY23 FY19 FY20 FY21 FY22 FY23 Approved ANDAs Injectable 8 Inhalation Derma 2 ➢ Well-established US front end with strong customer base 25 ➢ 6 products launched in Q4FY23. Cumu
Slide 12: Ex-US Generics
Ex-US Generics Revenue : Q4 FY23 INR Bn Revenue – Last 5 Years INR Bn 2.49 CAGR - 15% 1.88 8.52 7.79 7.75 Q4FY22 Q4FY23 4.94 4.97 ➢ Ex-US driven by partnership. Delivered 15% CAGR over last 5 years. ➢ Presence in following key markets - Europe, Canada, Australia, Brazil and South Africa ➢ Future gro
Slide 13: API
API Revenue : Q4 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 11% 3.13 11.66 2.22 9.55 9.39 7.71 Q4FY22 Q4FY23 7.08 ➢ Growth of 41% on QoQ basis is led by high off-take and better product mix in Q4. ➢ 6 USDMFs filed in FY23. 131 Cumulative DMF filings with the US FDA. ➢ Expect steady growth for
Slide 14: R&D Dosage form wise ANDA approval and Launch
R&D Dosage form wise ANDA approval and Launch R&D Capabilities Q4FY23 FY23 Formulation : Vadodara and Hyderabad Dosage Forms Approval* Launch Approval* Launch OSD 4 3 13 9 API : Vadodara and Hyderabad Injectable - Gen - - 3 - Injectable - Onco 2 1 3 1 Bio Centre : Vadodara Ophthalmology 1 - 1 - *Inc
Slide 15: State of the art facilities and infrastructure
State of the art facilities and infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20 Oncology Oral Solids Jun’19 F2 – Panelav Oncology Injectables Oct’22 F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Mar’23 F4 –
Slide 16: Financials: Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn 56.53 INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 10.53 # 8.75 6.65 # 7.79 # 5.84 4.97 # FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 EBIDTA margin % Capex ROCE % INR Bn 30 6.97
Slide 17: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q4 FY2023 Earnings Presentation on 6ix